Introducing Kardia 12L: The first of its kind 12-lead portable ECG | Learn More

AliveCor Logo

Our Products

AFib Screening
Data Integration Solutions
KardiaCare Plus
KardiaComplete
Kardia 12L

New

KardiaMobile 6L
AliveCor K1000
KardiaStation
KardiaPro
Kardia ECG Devices

Our Solutions

Health Systems
Clinical Trials
Patient Engagement
Payors
Employers
OEMs
Veterans Affairs

About

Leadership
Mission
Clinical Research
Our AI
For Consumers
The Human Component Film
Newsroom
(855) 338-8800
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • (855) 338-8800
    • Mission
    • Careers
    • Research
    • Newsroom
    • FAQs
    • User Manuals
    • Compatibility
    • Shipping
    • (855) 338-8800
    • KardiaMobile Card
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

Handheld 6-Lead Validated for QT Monitoring

JAMAnetwork.com

In this diagnostic study, a standard 12-lead ECG measurement was compared to a 6-lead device in a tuberculosis trial. Performed in South Africa, the study assessed 191 participants. Triplicate reference standard 12-lead ECG results were human calibrated with readers blinded to 6-lead ECG results.

At a QTc interval threshold of 500 milliseconds, the 6-lead device had a high negative predictive value of 99.8%.

This study suggests that simplified, handheld 6-lead ECG devices are effective triage tests that could reduce the need to perform standard 12-lead ECG monitoring in resource-constrained settings.

Key Takeaways:

  • At a diagnostic cut point of 500 milliseconds, 98.8% of clinic visits (483 of 489) were correctly classified by the handheld 6-lead device:
    • 482 as true negatives (ie, QTc interval <500 milliseconds measured by both devices)
    • 1 as true positive (ie, QTc interval of ≥500 milliseconds measured by both devices)
  • In resource-limited settings where QT screening is needed, the 6-lead device can be a cost-effective (20-50 times less costly than the conventional ECG), efficient, and reliable triage tool, resulting in more patient-centered care
  • There is proven diagnostic accuracy, repeatability, and feasibility with the 6-lead device

Read Full Article

Clinical Evidence

Handheld 6-Lead Validated for QT Monitoring

JAMAnetwork.com | A 6-lead device transforms cardiac care in resource-limited settings. This study in JAMA highlights its accuracy in monitoring QT intervals, reducing standard 12-lead ECG dependency, and easing access to cardiac care.

Remote Monitoring in Decentralized Trials

JAMAnetwork.com | Patient-centric trials require accessible digital health technologies. A JAMA study explores the current state and aspired role of remote monitoring and data collection tools in oncology trials.

KardiaMobile® 6L vs 12-lead ECG Impact on Clinic Time

Wiley.com | Clinic utilization time is significantly reduced with the KardiaMobile® 6L compared to traditional 12-lead ECG systems. This study published in Wiley highlights how KardiaMobile 6L minimizes the need for frequent conventional 12-lead use.